ProPhase Labs (PRPH) Stock Price, News & Analysis

Company Overview

ProPhase Labs, Inc. is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies. The company’s lab services cater to hospitals, clinics and physician practices by providing timely, accurate results that support patient care and public health monitoring. On the therapeutic side, ProPhase Labs markets a portfolio of over-the-counter products designed to relieve symptoms of cold and flu, including nasal inhalers and throat sprays, alongside branded disinfectants and personal care items.

ProPhase Labs also provides contract manufacturing and packaging services for third-party health and wellness companies, overseeing formulation, sterile filling and quality-control testing within its U.S. facilities. Through these integrated offerings, the company serves a broad domestic customer base in the healthcare, retail and institutional markets. Management continues to focus on expanding its diagnostic test menu and consumer product lines, leveraging regulatory expertise and manufacturing capabilities to support future growth.

Key Stats

• Today's Range: $0.41 to $0.46
• 50-Day Range: $0.28 to $0.52
• 52-Week Range: $0.22 to $2.72
• Volume: 1.19 million shs
• Average Volume: 2.51 million shs
• Market Capitalization: $17.86 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ProPhase Labs Stock Analysis - MarketRank™

ProPhase Labs scored higher than 24% of companies evaluated by MarketBeat, and ranked 869th out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ProPhase Labs.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ProPhase Labs are expected to grow in the coming year, from ($1.27) to ($0.56) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ProPhase Labs is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ProPhase Labs is -0.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ProPhase Labs has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.53% of the float of ProPhase Labs has been sold short.

Short Interest Ratio / Days to Cover

ProPhase Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProPhase Labs has recently decreased by 62.69%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProPhase Labs does not currently pay a dividend.

Dividend Growth

ProPhase Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.53% of the float of ProPhase Labs has been sold short.

Short Interest Ratio / Days to Cover

ProPhase Labs has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProPhase Labs has recently decreased by 62.69%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.89

News Sentiment

ProPhase Labs has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for ProPhase Labs this week, compared to 1 article on an average week.

Search Interest

6 people have searched for PRPH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

1 people have added ProPhase Labs to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ProPhase Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 9.60% of the stock of ProPhase Labs is held by insiders.

Percentage Held by Institutions

Only 9.45% of the stock of ProPhase Labs is held by institutions.

PRPH Stock Analysis - Frequently Asked Questions

How have PRPH shares performed this year?

ProPhase Labs' stock was trading at $0.7571 on January 1st, 2025. Since then, PRPH stock has decreased by 43.2% and is now trading at $0.4299.

How were ProPhase Labs' earnings last quarter?

ProPhase Labs, Inc. (NASDAQ:PRPH) issued its quarterly earnings data on Wednesday, August, 13th. The company reported ($0.11) EPS for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. The company earned $1.25 million during the quarter, compared to analysts' expectations of $3.55 million.
Read the conference call transcript.

Who are ProPhase Labs' major shareholders?

Top institutional shareholders of ProPhase Labs include Sykon Capital LLC (1.55%), Quinn Opportunity Partners LLC (0.53%), XTX Topco Ltd (0.25%) and Group One Trading LLC.
View institutional ownership trends.

How do I buy shares of ProPhase Labs?

Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ProPhase Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProPhase Labs investors own include Meta Platforms (META), Pfizer (PFE), Valero Energy (VLO), CymaBay Therapeutics (CBAY), Catalyst Pharmaceuticals (CPRX) and Energy Transfer (ET).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/15/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRPH
• CIK: 868278
• Web: www.prophaselabs.com
• Phone: (215) 345-0919
• Fax: 215-345-5920
• Employees: 130
• Year Founded: 1981

Profitability

• EPS (Trailing Twelve Months): ($1.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$53.36 million
• Net Margins: N/A
• Pretax Margin: -623.85%
• Return on Equity: -262.42%
• Return on Assets: -76.48%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 0.96
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: $6.77 million
• Price / Sales: 2.64
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.25 per share
• Price / Book: 1.72

Miscellaneous

• Outstanding Shares: 41,540,000
• Free Float: 37,553,000
• Market Cap: $17.86 million
• Optionable: Optionable
• Beta: -0.78